Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Analysts at Leede Financial raised their FY2025 earnings per share (EPS) estimates for shares of Medexus Pharmaceuticals in a note issued to investors on Wednesday, January 22nd. Leede Financial analyst D. Loe now expects that the company will post earnings of $0.29 per share for the year, up from their prior estimate of $0.20. Leede Financial has a "Strong-Buy" rating on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals' FY2027 earnings at $0.69 EPS and FY2028 earnings at $1.30 EPS.
A number of other equities research analysts also recently commented on the stock. Raymond James raised shares of Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 target price for the company in a research report on Wednesday, January 8th. Ventum Cap Mkts raised Medexus Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 17th. Alliance Global Partners raised Medexus Pharmaceuticals to a "strong-buy" rating in a report on Monday, December 23rd. Finally, Stifel Nicolaus boosted their price target on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a buy rating and five have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Medexus Pharmaceuticals currently has a consensus rating of "Strong Buy" and an average price target of C$5.58.
Check Out Our Latest Stock Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Performance
Shares of MDP stock traded down C$0.28 during trading hours on Thursday, reaching C$4.47. The company had a trading volume of 321,718 shares, compared to its average volume of 138,554. The business has a fifty day moving average price of C$3.14 and a 200-day moving average price of C$2.69. Medexus Pharmaceuticals has a one year low of C$1.47 and a one year high of C$5.56. The firm has a market cap of C$109.65 million, a PE ratio of 89.40 and a beta of 1.96.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Read More
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
